Advertisement
Canada markets open in 2 hours 30 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7322
    -0.0001 (-0.02%)
     
  • CRUDE OIL

    84.11
    +0.54 (+0.65%)
     
  • Bitcoin CAD

    87,562.43
    +861.87 (+0.99%)
     
  • CMC Crypto 200

    1,387.21
    -9.32 (-0.67%)
     
  • GOLD FUTURES

    2,360.70
    +18.20 (+0.78%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,738.50
    +171.00 (+0.97%)
     
  • VOLATILITY

    15.64
    +0.27 (+1.76%)
     
  • FTSE

    8,116.39
    +37.53 (+0.46%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Five Star Equities Issues New Research Reports on AMAG, CREE, DGX and EAT

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG - News) shares declined increased 0.91 percent to close at $21.06 a share Tuesday. The stock traded between $20.48 and $21.36 on volume 279,251 shares traded. The company announced that the FDA has rejected its supplemental new drug application for Feraheme injection for intravenous use. Shares of AMAG Pharmaceuticals have gained approximately 36.0 percent in the past year.

Get more information on AMAG Pharmaceuticals free access to the in-depth equity report at:
www.FiveStarEquities.com/AMAG

Cree, Inc. (NASDAQ:CREE - News) shares declined 5.93 percent to close at $63.34 a share Thursday. The stock traded between $62.19 and $66.59 on volume 5.66 million shares traded. The company reported record revenues of $346.3 million for the second quarter of 2014, an increase of 20.0 percent when compared to a year ago. Shares of Cree have gained approximately 85.0 percent in the past year.

ADVERTISEMENT

Get more information on Cree and free access to the in-depth equity report at:
www.FiveStarEquities.com/CREE

Quest Diagnostics Inc. (NYSE:DGX - News) shares declined 1.16 percent to close at $54.45 a share Thursday. The stock traded between $54.12 and $54.92 on volume of 1.48 million shares traded. The company announced that it has acquired Solstas Lab Partners Group and its subsidiaries for approximately $570.0 million. Shares of Quest Diagnostics have fallen approximately 10.0 percent in the past year.

Get more information on Quest Diagnostics and free access to the in-depth equity report at:
www.FiveStarEquities.com/DGX

Brinker International, Inc. (NYSE:EAT - News) shares gained 1.05 percent to close at $50.24 a share Thursday. The stock traded between $49.22 and $50.74 on volume 1.66 million shares traded. The company reported a net income of $39.7 million, or $0.58 per share, for the second quarter of fiscal 2014, an increase of 7.0 percent when compared to a year ago. Shares of Brinker International have gained approximately 50.0 percent in the past year.

Get more information on Brinker International and free access to the in-depth equity report at:
www.FiveStarEquities.com/EAT

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
info@fivestarequities.com